(NASDAQ:EXLS), NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) — EXL [NASDAQ: EXLS], a global data and AI company, today announced that, as part of its capital allocation program, it has entered into an accelerated share repurchase agreement (the “ASR”) with Citibank, N.A. to repurchase $125 million of the company's common stock. Chairman and Chief Executive […]
EXL announces $125 million accelerated share repurchase program GlobeNewswire July 29, 2025 NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) — EXL [NASDAQ: EXLS], a global data and AI company, today announced that, as part of its capital allocation program, it has entered into an accelerated share repurchase agreement (the “ASR”) with Citibank, N.A. to repurchase
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2025 financial results on Thursday, August 7, 2025, after the U.S. financial markets close. https://mma.prnewswire.com/media/1273133/Dynavax_Logo.jpg Dynavax will host a conference call and live audio webcast on Thursday, August 7, 2025, at 4:30 p.m. ET/1:30 p.m. PT.
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the second quarter 2025 following the close of market on Tuesday, Aug. 12, 2025. Following the release, company management will host a webcast and conference call at
(NASDAQ:ACRS), – Primary Endpoint Analysis Confirms Favorable Tolerability Profile of ATI-2138 Without Certain Risks Associated with Other Agents in the Class – – Efficacy Results Show Comparable Outcomes to Approved Therapies with Potential for Improved Tolerability, Supporting Exploration of Higher Doses in Future Clinical Trials – – Pharmacodynamic Results Validate Therapeutic Potential of ITK Inhibition
(NasdaqGM:LRMR), BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so
(NasdaqGM:BBNX), IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) — Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended June 30, 2025 and raised its full year guidance for the year ending December 31, 2025. Second Quarter 2025 Financial Results
Beta Bionics Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Guidance GlobeNewswire July 29, 2025 IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) — Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended June 30, 2025 and
Larimar Therapeutics Announces Proposed Underwritten Public Offering GlobeNewswire July 29, 2025 BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and,
Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints GlobeNewswire July 29, 2025 – Primary Endpoint Analysis Confirms Favorable Tolerability Profile of ATI-2138 Without Certain Risks Associated with Other Agents in the Class –